

ASCO 2011

**Poster discussion**

**Correlation of germ-line *BRCA2* mutations with aggressive prostate cancer and outcome.**

**Correlation of germ-line *BRCA2* mutations with aggressive prostate cancer and outcome.**

Author(s): **E. Castro**, C. L. Goh, **D. Olmos**, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, L. O'Brien, E. Sawyer, A. Hall, R. Wilkinson, Z. Kote-Jarai, R. A. Eeles, The UKGPCS collaborators.

Sub-category:

[Cancer Genetics](#)

Category:

Cancer Prevention/Epidemiology, **Poster discussion**

Meeting:

[2011 ASCO Annual Meeting](#)

Abstract No:

1517

Citation:

J Clin Oncol 29: 2011 (suppl; abstr 1517)

.....  
**General Poster**

**An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.**

Author(s): **D. Olmos**, J. Clark, D. Brewer, L. Barwell, G. Attard, A. H. Reid, S. K. Sandhu, A. Zivi, D. Bianchini, N. Babu Oomen, E. Thompson, L. R. Molife, S. B. Kaye, C. Parker, C. Cooper, R. J. Jones, J. S. De Bono.

Sub-category:

[Prostate Cancer](#)

Category:

Genitourinary Cancer

Meeting:  
[2011 ASCO Annual Meeting](#)

Abstract No:  
4577

Citation:  
J Clin Oncol 29: 2011 (suppl; abstr 4577)

**Sunday, June 5, 2011**

**8:00 AM - 12:00 PM**  
**GENERAL POSTER SESSION**  
**Genitourinary Cancer**  
Location: Hall A

Track(s): Genitourinary Cancer

.....  
**ORAL ABSTRACT**

**Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel**

H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu, C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila, M. Fleisher, **D. Olmos**, C. M. Haqq, J. S. De Bono

Sub-category:  
[Prostate Cancer](#)

Category:  
Genitourinary Cancer

Meeting:  
[2011 ASCO Annual Meeting](#)

Abstract No:  
LBA4517

Citation:  
J Clin Oncol 29: 2011 (suppl; abstr LBA4517)

.....  
**ORAL ABSTRACT**

**A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.**

A. W. Tolcher, R. D. Baird, A. Patnaik, **V. Moreno Garcia**, K. P. Papadopoulos, C. R. Garrett, **D. Olmos**, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono

Sub-category:

[Signal Transduction](#)

Category:

Developmental Therapeutics - Experimental Therapeutics

Meeting:

[2011 ASCO Annual Meeting](#)

Abstract No:

3004

Citation:

J Clin Oncol 29: 2011 (suppl; abstr 3004)

.....  
**General Poster**

**Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.**

Author(s): J. E. Ang, **D. Olmos**, **V. Moreno Garcia**, A. Brunetto, D. Papadatos-Pastos, H. Arkenau, **M. Blanco**, R. D. Baird, P. A. Cassier, D. S. W. Tan, R. S. Kristeleit, S. Dolly, K. J. Shah, B. Amin, B. G. Anghan, L. R. Molife, U. Banerji, J. S. De Bono, S. B. Kaye

Sub-category:

[Other](#)

Category:

Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Meeting:

[2011 ASCO Annual Meeting](#)

Abstract No:  
2555

Citation:  
J Clin Oncol 29: 2011 (suppl; abstr 2555)

.....

**ADEMÁS**

**Exemestane for primary prevention of breast cancer in postmenopausal women:  
NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. (3528)**

Sub-category:  
[Prevention](#)

Category:  
Breast Cancer - HER2/ER

Meeting:  
[2011 ASCO Annual Meeting](#)

Abstract No:  
LBA504

Citation:  
J Clin Oncol 29: 2011 (suppl; abstr LBA504)

Author(s): P. E. Goss, J. N. Ingle, **J. Ales-Martinez**, A. Cheung, R. T. Chlebowski, J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J. E. Garber, C. J. Fabian, P. Pujol, E. Maunsell, P. Farmer, K. A. Gelmon, D. Tu, H. Richardson

**Attend this session at the  
ASCO Annual Meeting!**

**Session: Breast Cancer - HER2/ER**

**Type:** Oral Abstract Session

**Time:** Sunday June 5, 9:00 AM to 12:00 PM

**Location:** McCormick Place Hall B1

.....

**COMUNICACIONES/ POSTER A PRESENTAR EN ASCO 2011  
GEICAM**

- Goss P, Ingle J, Alés-Martínez JE, Man-Wei-Cheung A, Chlebowski L, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winqvist E, Sarto G, Garber J, Fabian C, Pujol P, Maunsell E, Farmer P, Gelmon K, Tu D, Richardson H. **Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial.** Comunicación oral aceptada en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr LBA504)
- Bernard PS, Davis C, Munarriz B, Stijleman IJ, Ruiz-Borrego M, Ebbert MTW, Rodriguez-Lescure A, Bastien RRL, Crespo C, Perou CM, Rodriguez C, Aranda F I, Furio V, Alvarez I, Seguí MA, Alba E, Anton A, Carrasco EM, Caballero R, Martin M. **Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial.** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr 611)
- Ruiz-Borrego M, Barrios CH, Lluch A, Bines J, Segalla JGM, Ruiz A, Torrecillas L, Llombart-Cussac A, Torres R, Garcia Saenz JÁ, Lopez Garcia-Asenjo JA, Gomez HL, De la Haba JR, Reyes S, Martinez E, Baena JM, Perez-Michell L, Rodriguez-Lescure A, Anton A, Martin M, on behalf of CIBOMA/GEICAM. **Local vs. central laboratory discrepancies in the determination of triple negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts).** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr 1022)
- Alba E, Chacon JI, Lluch A, García-Estevez L, Anton A, Cirauqui B, Lopez Garcia-Asenjo JA, Carrasco EM, Rodriguez C, Escudero MJ, Sanchez A, Ribelles N, Romero C, Alvarez J, Albanell J, on behalf of Spanish Breast Cancer Research Group (GEICAM). **Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in basal-like breast cancer patients. GEICAM 2006-03, a multicenter, randomized phase II study.** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr 1015)

- Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz-Mateu M, Caronia D, Carrasco EM, Garcia Saenz JÁ, Casado A, Chacón I, Hernando B, Ruiz-Borrego M, Gonzalez-Neira A. **Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study.** Comunicación oral aceptada en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr 1008)
- Munoz-Mateu M, Urruticoechea A, Separovic R, Erfán J, Bachelot TD, Canon JL, Kovalenko N, Staroslawska E, Pikó B, Veyret C, Pribylova O, Ciule DL, Ratnayake J, Das S, Mayne K, Ross G. **Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, Phase II study (PHEREXA).** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr TPS118)
- Amadori D, La Torre I, Carrasco EM, Roesel S, Labianca R, Moreau-Donnet V, Desai D, Martin M. **A randomized phase II study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr 1051)
- Goss PE, Barrios CH, Chan A, Chia SKL, Delaloge S, Ejlertsen B, Ingle JN, Moy B, Iwata H, Holmes FA, Mansi J, Von Minckwitz G, Han L, Thiele A, Agrapart V, Freyman A, Truscetto J, Berkenblit A, Finkelstein D. **A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC).** Poster aceptado en: 47<sup>th</sup> American Society Clinical Oncology Annual Meeting. 3-7 Junio 2011. Chicago. USA. J Clin Oncol 29: 2011 (suppl; abstr TPS137)